Serum levels of bilirubin as an independent predictor of coronary in-stent restenosis: A new look at an old molecule

Journal of Atherosclerosis and Thrombosis

Volumn 18, Issue 7, 2011, Pages 574-583

  Kuwano, Takashi ^a   Miura, Shin Ichiro ^a   Shirai, Kazuyuki ^b   Ike, Amane ^a   Mori, Ken ^a   Shimizu, Tomohiko ^a   Zhang, Bo ^a   Iwata, Atsushi ^a   Nishikawa, Hiroaki ^a   Kawamura, Akira ^a   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Hakujuji Hospital   (Japan)

Author keywords

Bilirubin; Coronary artery disease; Percutaneous coronary intervention; Restenosis; Stent

Indexed keywords

BILIRUBIN;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; BILIRUBIN BLOOD LEVEL; CORONARY ARTERY DISEASE; CORONARY STENT; FEMALE; FOLLOW UP; HUMAN; IN STENT RESTENOSIS; MAJOR CLINICAL STUDY; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; RESTENOSIS; RISK FACTOR;

AGED; ANGIOGRAPHY; ANGIOPLASTY, BALLOON; BILIRUBIN; CELL PROLIFERATION; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK; RISK FACTORS; STENTS;

EID: 79960872513     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.6643     Document Type: Article

References (34)

1. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE: Sirolimuseluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med, 2003; 349: 1315-1323
2. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME: A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med, 2004; 350: 221-231
3. Ortolani P, Balducelli M, Marzaroli P, Piovaccari G, Menozzi A, Guiducci V, Sangiorgio P, Tarantino F, Geraci G, Castriota F, Tondi S, Saia F, Cooke RM, Guastaroba P, Grilli R, Marzocchi A, Maresta A: Two-year clinical outcomes with drug-eluting stents for diabetic patients with de novo coronary lesions: results from a real-world multicenter registry. Circulation, 2008; 117: 923-930
4. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabate M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Juni P: Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet, 2007; 370: 937-948
5. Hoffmann R, Mintz GS, Dussaillant GR, Popma JJ, Pichard AD, Satler LF, Kent KM, Griffin J, Leon MB: Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation, 1996; 94: 1247-1254
6. Welt FG, Rogers C: Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol, 2002; 22: 1769-1776
7. Chung IM, Gold HK, Schwartz SM, Ikari Y, Reidy MA, Wight TN: Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment. J Am Coll Cardiol, 2002; 40: 2072-2081
8. Liu MW, Roubin GS, King SB, 3rd: Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia. Circulation, 1989; 79: 1374-1387
9. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN: Bilirubin is an antioxidant of possible physiological importance. Science, 1987; 235: 1043-1046
10. Novotny L, Vitek L: Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp Biol Med (Maywood), 2003; 228: 568-571
11. Schwertner HA, Jackson WG, Tolan G: Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem, 1994; 40: 18-23
12. Breimer LH, Wannamethee G, Ebrahim S, Shaper AG: Serum bilirubin and risk of ischemic heart disease in middle-aged British men. Clin Chem, 1995; 41: 1504-1508
13. Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM, Williams RR: Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arterioscler Thromb Vasc Biol, 1996; 16: 250-255
14. Vitek L, Jirsa M, Brodanova M, Kalab M, Marecek Z, Danzig V, Novotny L, Kotal P: Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis, 2002; 160: 449-456
15. Lin JP, O'Donnell CJ, Schwaiger JP, Cupples LA, Lingenhel A, Hunt SC, Yang S, Kronenberg F: Association between the UGT1A128 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation, 2006; 114: 1476-1481
16. Neuzil J, Stocker R: Free and albumin-bound bilirubin are efficient co-antioxidants for alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation. J Biol Chem, 1994; 269: 16712-16719
17. Stocker R, Ames BN: Potential role of conjugated bilirubin and copper in the metabolism of lipid peroxides in bile. Proc Natl Acad Sci U S A, 1987; 84: 8130-8134
18. Ollinger R, Yamashita K, Bilban M, Erat A, Kogler P, Thomas M, Csizmadia E, Usheva A, Margreiter R, Bach FH: Bilirubin and biliverdin treatment of atherosclerotic diseases. Cell Cycle, 2007; 6: 39-43
19. Ollinger R, Bilban M, Erat A, Froio A, McDaid J, Tyagi S, Csizmadia E, Graca-Souza AV, Liloia A, Soares MP, Otterbein LE, Usheva A, Yamashita K, Bach FH: Bilirubin: a natural inhibitor of vascular smooth muscle cell proliferation. Circulation, 2005; 112: 1030-1039
20. Takebayashi H, Mintz GS, Carlier SG, Kobayashi Y, Fujii K, Yasuda T, Costa RA, Moussa I, Dangas GD, Mehran R, Lansky AJ, Kreps E, Collins MB, Colombo A, Stone GW, Leon MB, Moses JW: Nonuniform strut distribution correlates with more neointimal hyperplasia after sirolimuseluting stent implantation. Circulation, 2004; 110: 3430-3434
21. Kastrati A, Dibra A, Mehilli J, Mayer S, Pinieck S, Pache J, Dirschinger J, Schomig A: Predictive factors of restenosis after coronary implantation of sirolimus-or paclitaxeleluting stents. Circulation, 2006; 113: 2293-2300
22. Rathore S, Terashima M, Katoh O, Matsuo H, Tanaka N, Kinoshita Y, Kimura M, Tuschikane E, Nasu K, Ehara M, Asakura K, Asakura Y, Suzuki T: Predictors of angiographic restenosis after drug eluting stents in the coronary arteries: contemporary practice in real world patients. EuroIntervention, 2009; 5: 349-354
23. Mintz GS: Features and parameters of drug-eluting stent deployment discoverable by intravascular ultrasound. Am J Cardiol, 2007; 100: 26M-35M
24. Nakao A, Murase N, Ho C, Toyokawa H, Billiar TR, Kanno S: Biliverdin administration prevents the formation of intimal hyperplasia induced by vascular injury. Circulation, 2005; 112: 587-591
25. Endler G, Exner M, Schillinger M, Marculescu R, Sunder-Plassmann R, Raith M, Jordanova N, Wojta J, Mannhalter C, Wagner OF, Huber K: A microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with increased bilirubin and HDL levels but not with coronary artery disease. Thromb Haemost, 2004; 91: 155-161
26. Chen YH, Chau LY, Lin MW, Chen LC, Yo MH, Chen JW, Lin SJ: Heme oxygenase-1 gene promotor microsatellite polymorphism is associated with angiographic restenosis after coronary stenting. Eur Heart J, 2004; 25: 39-47
27. Schillinger M, Exner M, Minar E, Mlekusch W, Mullner M, Mannhalter C, Bach FH, Wagner O: Heme oxygenase-1 genotype and restenosis after balloon angioplasty: a novel vascular protective factor. J Am Coll Cardiol, 2004; 43: 950-957
28. Chen YH, Chau LY, Chen JW, Lin SJ: Serum bilirubin and ferritin levels link heme oxygenase-1 gene promoter polymorphism and susceptibility to coronary artery disease in diabetic patients. Diabetes Care, 2008; 31: 1615-1620
29. Lin R, Wang X, Wang Y, Zhang F, Fu W, Yu T, Li S, Xiong M, Huang W, Jin L: Association of polymorphisms in four bilirubin metabolism genes with serum bilirubin in three Asian populations. Hum Mutat, 2009; 30: 609-615
30. Tiroch K, Koch W, von Beckerath N, Kastrati A, Schomig A: Heme oxygenase-1 gene promoter polymorphism and restenosis following coronary stenting. Eur Heart J, 2007; 28: 968-973
31. Ko GT, Chan JC, Woo J, Lau E, Yeung VT, Chow CC, Li JK, So WY, Cockram CS: Serum bilirubin and cardiovascular risk factors in a Chinese population. J Cardiovasc Risk, 1996; 3: 459-463
32. Chin HJ, Cho HJ, Lee TW, Na KY, Oh KH, Joo KW, Yoon HJ, Kim YS, Ahn C, Han JS, Kim S, Jeon ES, Jin DC, Kim YL, Park SH, Kim CD, Song YR, Kim SG, Kim YG, Lee JE, Oh YK, Lim CS, Lee SK, Chae DW, Cho WY, Kim HK, Jo SK: The mildly elevated serum bilirubin level is negatively associated with the incidence of end stage renal disease in patients with IgA nephropathy. J Korean Med Sci, 2009; 24 Suppl: S22-29
33. Fukui M, Tanaka M, Shiraishi E, Harusato I, Hosoda H, Asano M, Hasegawa G, Nakamura N: Relationship between serum bilirubin and albuminuria in patients with type 2 diabetes. Kidney Int, 2008; 74: 1197-1201
34. Targher G, Bosworth C, Kendrick J, Smits G, Lippi G, Chonchol M: Relationship of serum bilirubin concentrations to kidney function and albuminuria in the United States adult population. Findings from the National Health and Nutrition Examination Survey 2001-2006. Clin Chem Lab Med, 2009; 47: 1055-1062